Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
February 15, 2022- After review of more than 448 enrolled patients in ACTIV-3b Critical Care Study, no new safety concerns identified by Independent Data Safety Monitoring Board; study cleared to continue enrollment to 640 PatientsNRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today announced results of a review conducted by the Therapeutics and Prevention Data Safety and Monitoring Board...
-
February 11, 2022•Remarks by Dr. Shmuel Yitzhaki, as published in Globes, an Israeli business newspaper
RADNOR, Pa., Feb. 11, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today reported remarks by Dr. Shmuel Yitzhaki, Director of the...
-
February 2, 2022
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP (or the "Company"), a Delaware corporation, today announced that it has closed its previously announced private placement priced at a premium to market...
-
January 30, 2022
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 7,824,727 shares of...
-
January 27, 2022- Israel Institute for Biological Research files initial scientific results of BriLife vaccine effectiveness in producing neutralizing antibody against Omicron Variant
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine...
Click here to view our corporate presentation or on the image below
 |
